UBX-303

N/A

Report date: 2024/09/24 14:16:58
NME

Base Information

Drug NameUBX-303
Drug Alias NameUBX-303UBX-303-1
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionTyrosine-protein kinase BTK degraders
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUbix Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUbix Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A